PR-39, a proline/arginine-rich antimicrobial peptide, prevents postischemic microvascular dysfunction
Department of Molecular and Cellular Physiology, Louisiana State University Medical Center, School of Medicine in Shreveport, Shreveport, Louisiana 71130; and Department of Anatomy and Physiology, Kansas State University, College of Veterinary Medicine, Manhattan, Kansas 66506 We and others have pre...
Gespeichert in:
Veröffentlicht in: | American journal of physiology. Heart and circulatory physiology 1999-09, Vol.277 (3), p.H1007-H1013 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Department of Molecular and Cellular Physiology, Louisiana State
University Medical Center, School of Medicine in Shreveport,
Shreveport, Louisiana 71130; and Department of Anatomy and Physiology,
Kansas State University, College of Veterinary Medicine, Manhattan,
Kansas 66506
We and others have previously demonstrated
that intestinal ischemia-reperfusion (I/R) is associated with a
large increase in oxidant production that contributes to microvascular
barrier disruption in the small bowel. It has been suggested that the bulk of tissue damage during reperfusion can be attributed to adherent,
activated neutrophils. From these observations, we hypothesized that
pretreatment with PR-39, an endogenous neutrophil antibacterial peptide
that is also a potent inhibitor of the neutrophil NADPH oxidase, would
prevent postischemic oxidant production and the development of
oxidant-dependent sequelae to I/R such as increased venular protein
leakage. To test this postulate, oxidant production, venular protein
leakage, leukocyte adhesion, and leukocyte emigration were monitored
during reperfusion in control (no ischemia) rat mesenteric
venules and in mesenteric venules subjected to I/R alone or PR-39 + I/R. Treatment with a single intravenous bolus injection of PR-39
(administered at a dose to achieve an initial blood concentration of 5 µM) abolished I/R-induced leukocyte adhesion and emigration in vivo.
In vitro studies indicated that PR-39 prevents platelet-activating
factor-induced neutrophil chemotaxis as well as phorbol myristate
acetate (PMA)-stimulated intercellular adhesion molecule-1 expression
by cultured endothelial cells. PR-39 pretreatment of rat neutrophils
also blocked PMA-stimulated neutrophil adhesion to activated
endothelial monolayers. In vivo, I/R was associated with a marked and
progressive increase in oxidant production and venular protein leakage
during reperfusion, effects that were abolished by PR-39 treatment. The
results of this study indicate that PR-39 completely abolishes
postischemic leukocyte adhesion and emigration. The time course for
inhibition of oxidant production by PR-39 suggests that its
antiadhesive properties account for this effect of the peptide. PR-39
may thus be therapeutically useful for prevention of neutrophil
adhesion and activation during the postischemic inflammatory response.
leukocyte adhesion; leukocyte emigration; venular protein leakage; oxidant production; intravital microscopy; intercellular adhesion
molecule-1 |
---|---|
ISSN: | 0363-6135 0002-9513 1522-1539 |
DOI: | 10.1152/ajpheart.1999.277.3.h1007 |